# I. Introduction ndian economy is currently booming. More and more Indian industries and companies are expanding their activities in foreign markets. It is seen that the destination, mode of internationalization and motivations for global expansion are changing. Literature has established the factors that are most influential in deciding the modes of internationalization for Indian pharmaceutical companies. It was considered important to validate the results by evaluating the current scenario and trends for modes of internationalization in the industry. Therefore, a detailed analysis of five leading pharmaceutical companies of India is conducted. These companies have extensive experience in both domestic as well as foreign markets and therefore warranted a detailed study on their approach and experience in various modes of internationalization. This paper lays out the detailed internationalization efforts of top 5 Indian pharmaceutical companies. These companies were ranked based on their revenue . Top 5 companies by revenue were selected from the big size category. These companies are Sun Pharma, Dr. Reddy's laboratories, Cipla, Lupin and Aurobindo Pharmaceuticals. This category is the most active in internationalization efforts and have gone through multiple modes of internationalization in their evolution. Complete history of the companies is studied to understand the reasons for various modes of internationalization decisions during different stages of the company's life. Table 1 below details out some general characteristics of these companies. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. It has a presence in key therapeutic segments such as neurosciences, cardiovascular, antiretrovirals, anti -diabetics, gastroenterology and cephalosporin, among others. The company entered the specialty generic formulations segment through cost effective manufacturing capabilities. Today, after a decade or so, it has evolved into a global company manufacturing API's and formulation products based on its innovation capabilities. Aurobindo's R&D capabilities has resulted in filing of multiple patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. In fact, AurobindoPharma is among the largest filers of DMFs and ANDAs from India. Aurobindo exports to over 125 countries across the globe. Around 70% of its revenues are derived out of international operations. It's manufacturing units have been approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada and Brazil ANVISA. Aurobindo Pharma Ltd. has evolved into a knowledge driven, R & D focused company, with its manufacturing and marketing infrastructure spread across many countries. Aurobindo has invested significant resources in regulated markets by designing five of its units for APIs and five units for Finished Dosages. These units are approved by US FDA, UKMHRA, WHO, MCC-SA, ANVISA-Brazil, and TGI-Australia. Aurobindo has a robust product portfolio of over 400 generic specialties. # b) Path to Internationalization Aurobindo has been very active in the international pharmaceutical space. Aurobindo started internationalizing in the 1990's by setting up subsidiaries in various countries. This was followed by doing strategic acquisitions in 2000's to enhance company's product portfolio and access new markets. Table 2.2 below details the international operations of Aurobindo. Aurobindo Pharma concluded a strategic deal to acquire Italian operations of Germany based TAD Pharmaceuticals in 2007. This acquisition gave Aurobindo access to more than 70 ready to market products. This strategic acquisition is expected to jump start the business for Aurobindo in Italy where the market and the regulatory procedures are considered as the one of the toughest in all EU. Aurobindo also acquired high profile OTC brands -Mapooro and Carmiooro from TAD as a part of this deal. This was company's third acquisition in Europe, after acquiring Milpharm Ltd in UK and Pharmac in International B.V., in Netherlands. The Company believes that such acquisitions reduce the time to market and enhance the relationships in the generic value chain in addition to building a broad and formidable product portfolio. To conclude it can be said that Aurobindo-Pharma has identified international operations as a major part of its growth strategy. It has been gradually expanding its global network of marketing and manufacturing operations. Geographically, its focus has been majorly on China, Brazil, Japan, Netherlands, South Africa, Thailand, UK, USA and Russia. It can be said that subsidiary has been its most preferred modes of internationalization. Aurobindo is today well positioned to surmount any further challenge in international expansion. # c) Analysis & Conclusion # III. Cipla Pharmaceuticals Cipla is a global pharmaceutical company. It is one of the oldest pharmaceutical companies in India and is present in more than 170 countries across the world. The list of countries includes the U.S., Canada and countries in Europe, Africa, Australia, Latin America and the Middle East. Cipla's research and development focuses on developing innovative products and drug delivery systems. It has been responsible for creating multiple new products that are accepted in India as well as globally. Despite the tightly regulated environment of foreign countries, Cipla today has more than 30 manufacturing facilities across India that have been approved by major international regulatory agencies including US FDA, MHRA-UK, WHO, Department of Health-Canada, MCC -South Africa, ANVISA -Brazil, and PMDA -Japan. The company engages in R&D and also offers technical consultancy services. CIPLA's R&D focuses on innovation, both product and process, that result in cost and time saving. CIPLA has gained expertise in producing generics of very complex molecules. The company has given many generic solutions to India and to the world. # b) Path to Internationalization The core of Cipla's international business is strategic alliances for product development, registration and distribution of the products. Its international business continues to be a major revenue driver for the company. Their overseas sales represent 53% of the total income. Cipla continues to expand and modernize its manufacturing and Research & Development facilities. Table 7 As part of their growth strategy, Cipla acquired Celeris in 2013. It is a pharmaceutical distribution company based out of Croatia and was recently renamed as Cipla Croatia. In July 2014 Cipla signed an exclusive partnership with BioQuiddity (Europe based company) to market One Dose Ready fusORTM (a drug used in regional anesthetic applications for post-surgical pain management). Cipla also entered into an alliance with Serum Institute of India to launch vaccines in Europe. Currently, CIPLA is one of the world's largest generic pharmaceutical companies with its products sold in over 180 countries. So far, the main mode of international business is exports of formulations, Pharmaceutical ingredients, prescription and over-thecounter drugs, and veterinary products. However, going forward CIPLA is looking to make a shift in its business model. # c) Analysis & Conclusion Cipla is the oldest company amongst its Indian peers. It did not realize the benefit of mergers, acquisitions soon enough and so got left behind a little but is now catching up fast. Just like its peers in Top pharmaceutical companies of India, and as can be seen in Apart from Medpro's acquisition, CIPLA did not grow inorganically through mergers and acquisitions. The company has always expanded organically. Further, except Medpro, CIPLA's physical expansion always took place within India. This may be because any expansion outside India might have made CIPLA vulnerable for legal suites for the previous breach of intellectual property rights. Therefore, while operating from India, CIPLA conducted its international business through indirect exports. However, the company hopes that it will not face too many challenges when it moves abroad in the near future because it has partners across the globe to help with whom it has long standing relationships. Company is planning to undertake foreign direct investment for expansion in near future. The expansion is most likely to be a forward expansion as the company aims to build marketing and sales network in abroad. # IV. DR. Reddy Labs Dr. Reddy's Laboratories is an emerging global pharmaceutical company. It has three core businesses: Pharmaceutical Services and Active Ingredients, comprising Active Pharmaceuticals and Custom Pharmaceuticals businesses; Global Generics, which includes branded and unbranded generics; and Proprietary Products, which includes New Chemical Entities (NCEs), Differentiated Formulations, and Generic Biopharmaceuticals. Table 4.1 lists out some other basic facts about the company. Dr. Reddy's began as a supplier to Indian drug manufacturers. It soon started exporting to other lessregulated markets. This meant not having to spend time and money on a manufacturing plants or seek approval from a drug licensing body such as the U.S. Food and Drug Administration (FDA). This was a great advantage and helped spur the phenomenal growth of the company. By the early 1990s, bolstered by the expanded scale and profitability in unregulated markets, the company started focusing on tightly regulated markets. It started getting approvals from drug regulators for their formulations and bulk drug manufacturing plants in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. In 2001 Reddy's completed its US initial public offering of $132.8 million American Depositary Receipts (ADR) issue and also listed on the New York Stock exchange. Funds raised from the US initial public offering helped Reddy's move into international production -and take over technology -based companies. By 2007, Dr. Reddy's had six FDA-plants manufacturing active pharmaceutical ingredients in India. It also had seven FDA-inspected plants making patient-ready medications -five of them in India and two in the UK. Reddy's also invested heavily in building R&D labs and is the only Indian company to have significant R&D being undertaken overseas. Dr. Reddy's Research Foundation was established in 1992 and dedicated to research in area of new drug discovery. At first, the foundation's drug research strategy revolved around searching for analogues but its changed focus to innovative R&D by hiring new scientists. # b) Path to Internationalization Reddy's path into new drug discovery involved targeting specialty generics products in western markets to gain drug discovery abilities. This led Dr. Reddy to adopt aggressive merger & acquisition strategy to explore the international markets. Table 4.2 below lists out the internationalization history of the company. Dr. Reddy was a very early mover into the Russian market, forming a joint venture with the country's biggest pharmaceuticals producer Biomed in 1992. In 1993, Reddy's entered into a joint venture in the Middle East and created two formulation units there and in Russia. Reddy's exported bulk drugs to these formulation units, which then converted them into finished products. In 1994, Reddy's started targeting the US generic market by building state of art manufacturing facility. By 1997, Reddy's was ready for the next major step. From being an API and bulk drug supplier to regulated markets like the USA and the UK, and a branded formulations supplier in unregulated markets like India and Russia. In 2000, Dr. Reddy's Research Foundation set up a US lab in Atlanta, dedicated to discovery and design of novel therapeutics Reddy's merged Cheminor Drug Limited (CDL) with primary aim of supplying APIs to the technically demanding markets of North America and Europe. This merger also gave Reddy's entry into value added generics business in the regulated markets of APIs. In 2001 Reddy's became the first Indian company to launch the generic drug, fluoxetine (a generic version of Eli Lilly and Company's Prozac) with 180-day market exclusivity in the USA. The fluoxetine marketing success was followed by the launch of ibuprofen in US under its own brand name, in January 2003. It was the first step in building Reddy's fully fledged distribution network in the US market. In March 2002, Dr. Reddy's acquired BMS Laboratories, Beverley, and it is wholly owned subsidiary Meridian Healthcare, for EUR 14.81 million. Recently, Dr. Reddy's entered into an R&D and commercialization agreement with Argenta Discovery Ltd., a private drug development company based in the UK, for the treatment of COPD. With growing success in the generics market, Reddy's also came to realize the need for developing marketing and distribution capabilities in the USA. The company already had one tie-up with Pharmaceutical Resources, Inc. to market Fluoxentine 40 mg tablets. It also had a tie-up with Par Pharmaceuticals Inc., to produce and market over-the-counter drugs in the U.S. In addition to the United States, Reddy's generics business had established a presence in the UK as well. Reddy's also plans to expand its presence in Canada and South Africa. Its API business had sales in over 60 countries, with the US and India being the most significant revenue contributors. The branded formulations business was active in over 30 countries and Reddy's was a significant player in the Indian and Russian markets. The business planned to significantly increase its presence in China, Brazil and Mexico in the near future. In 2004, Reddy's acquired Trigenesis Therapeutics Inc.; the US based private dermatology company. This acquisition gave Reddy's access to certain products and proprietary technologies in dermatology segment. In March 2006, Dr. Reddy's acquired BetapharmArzneimittel GmbH from 3i for EUR 480 million. This is one of the largest-ever foreign acquisitions by an Indian pharmaceutical company. # c) Analysis & Conclusion Dr. Reddy's Labs has been a very aggressive player in the international acquisition space. Its initial success came through exports of generics which continue to be the growth drive to this date. Reddy's successful growth into a fully integrated pharmaceutical company in less than a decade was founded on a successful and targeted program of inorganic growth and investments in process R&D. It had chosen a high risk-high gain strategy to growth by going into direct competition with existing patent holders. A major challenge for Reddy's is to find ways to de-risk its overall strategy. One way may lie in managing the cash flows from the 'safer' API and formulations businesses. Another way may be to seek out more experienced partners for the R&D business or use acquisitions to boost R&D resources and revenues. It has chosen the global route and went on an acquiring spree. # V. Lupin Lupin is an innovation led transnational pharmaceutical major producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment. # b) Path to Internationalization Lupin is one of the largest and fastest growing pharmaceutical companies in India. It is present in more than 70 countries. Lupin has used a mix of international expansion strategies which reflect the need and stage in the growth life cycle of Lupin itself. Table 5.2 below shows the internationalization history of Lupin. # ( E ) In 2002-03 Lupin had already made inroads into the active pharmaceutical ingredient or API supplies in the US and Europe, but was a fringe player in most other markets. Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003. Since then company have received more than 75 FDA approvals and have become one of the fastest growing pharmaceutical companies in the US. Lupin operates a globally integrated network of 11 manufacturing facilities. Their world class facilities are built to manufacture and deliver a wide range of finished products to the US market. USA is the main market fir Lupin's operations. Lupin has experienced a wide degree of transformation. It has started with opening a subsidiary in USA to sell its while the same team is selling some other companies product in the country. Medicines in Japan have different specifications from other markets. The percentage of residual impurities and the raw material strengths are different from that of US or European requirements and therefore, cannot be clubbed together with those markets. As a result, Lupin revealed the first step in its strategy-a cooperation agreement with a 50-year old local drug firm Kyowa Pharmaceutical to market medicines in Japan. The agreement turned out to be pivotal. While Lupin had to develop and manufacture the medicine, Kyowa was supposed to conduct regulatory testing, obtain approvals and market the drugs in Japan. Two years later, Lupin acquired a majority stake in privately-held Kyowa, and in 2008, turned it into a 100 per cent subsidiary. Kyowa gave Lupin lot of insights into the working of the Japanese generic market. Company added new products in the Kyowa pipeline, and in less than three years, doubled its turnover. # c) Analysis & Conclusion Again, just like its peers in Top pharmaceutical companies of India, and as can be seen in Fig 5 .1 and 5.2 below, the export intensity has been directly correlated with R&D expenses as well as Total Assets. # Total Assets & Export Intensity Lupin Lupin started with the organics entry in international market. but with its strengths and capabilities it moved to other non-organic modes of expansion as well. Thus, it can be said that Lupin is set to emerge as a transnational enterprise from a purely Indian operation leveraging its ownership resources of low cost manufacturing and acquired R&D capabilities, tuning its strategies to enter markets with best location advantages and using its core competencies to internalize key functions and actually magnetizing these strategic assets. # VI. Sun Pharmaceuticals Laboratories # LTD. Sun Pharma is a global, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations in India, US and several other markets across the world. In India, the company manufactures products in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology. Several regulatory agencies, including FDA-USA, EMA-Europe, MHRA-UK, MCC-South Africa, TGA-Australia, ANVISA-Brazil, WHO-Geneva, BfArM-Germany, KFDA-Korea and PMDA-Japan, have certified their facilities. Their track-record of successful collaborations includes various in and out licensing of products and technologies, joint ventures, as well as mergers & acquisitions. Their early investments in R&D began three decades ago. It enabled the company to make technology as their key differentiator and develop a basket of robust products for diverse markets across the world. The company have around 1800 research scientists working in multiple R&D centers. Their scientists have expertise in developing generics, Active Pharmaceutical Ingredients (APIs), Novel Drug Delivery Systems (NDDS) and New Chemical Entities (NCEs). # b) Path to Internationalization Sun pharmaceutical started exporting products to neighboring countries of India in 1989. Table 6 Then in 1991, fall in bulk drug prices was a setback for the company. It realized the mistake of depending on a single product line so it started to diversify across multiple formulations. Russia became the biggest export market for Sun but the 1998 collapse of the Russian economy came as a big jolt for the company. Sun has become too focused on Russia as country and lost a big chunk of business due to the political upheaval. That's when Sun decided to focus on three key therapeutic areas by employing similar production technology. This allowed Sun to serve different market segments while using the same technology and thereby allowing them access to the best of both worlds. In 1997, Sun did its first international acquisition. The main purpose of the acquisition was to acquire the technology. As a result, Sun acquired many companies with equity stake. MJ Pharma, TDPL were few of them. Apart from acquisition as a mode of internationalization Sun also focused on exports. In 1997, Sun reported the exports as 18 percent of their total sales. Although Sun was present in many regulated and unregulated markets, USA still remained the single most important country. In 2004 Sun Pharma bought a few exclusive brands to consolidate its positions as a leader in the segment. The brands were purchased from the US based company Women's First Healthcare (WFHC). Acquisition of WFHC was the foundation stone for entering the branded generic space in the US at a reasonable cost. In same year Sun Pharma increased its stake in Coraco to over 60% from 44% by acquiring a common stock and options from 2 large shareholders of Caraco. In There is intense competition from API manufacturers in many other developing countries. Therefore, the company is trying to diversify its product offerings by targeting specialty API. The company's acquisition of Knoll's bulk drug facility and its purchase of controlling stakes in Gujarat Pharma, MJ Pharma, and Caraco (U.S.) provide Sun with additional R&D capabilities and access to U.S. FDA approved factories. As can be seen in Fig 6 .1, increase in R&D had a positive impact on export intensity of the company. After the thorough analysis it can always be said that Sun Pharma is internationalizing with a high pace, but still challenges are on the way. Sun is taking corrective measures to eliminate the threat of increased patent protection. It is investing heavily in sales and marketing capacities and plans to implement its branded generic strategy in multiple markets. # VII. Comparative Analysis of Findings From Case Studies The first step in internationalization for a small company is always exports. This would mainly be achieved by entering into an agreement with another company in that country. The guiding factor behind it is the philosophy of the company to count on quality. The small company prefers in investing in quality rather than marketing and distribution. Moreover, to encourage the exports they get various incentives from Indian government in form of duty drawbacks, duty free imports of raw materials etc. So it is not only the enthusiasm of the entrepreneur, but also the encouragement on behalf of government that leads to internationalization. As is evident from the table above that regulatory framework, R & D and Market Size have been some of the factors that have influenced the modes of internationalization decisions for these companies. Fig. 7.2 below further shows the R&D expenses at these 5 pharmaceutical firms. Mergers & Acquisitions are generally followed by larger companies. The guiding objective is either to enter a new market quickly or gain a dominant position in an existing market. Through acquisitions, company generally looks for market expansion and operational efficiency. Perhaps it can be said that mergers and acquisitions are generally guide by an objective of resource seeking. In the global world we live in today, there is cut throat competition at every level and it becomes imperative for firms to go for continuous product expansion and market expansion. This product and market expansion is achieved through mergers and acquisitions. # 0% Subsidiary route or establishing a manufacturing plant in the foreign country is followed by even fewer and largest companies as it is the most cost and time intensive approach. Setting up a new unit takes time as it requires getting all the approvals from local authorities. Acquisition has emerged as a dominant strategy for internationalization in Europe compared to the US and developing countries. Indian companies are acquiring firms in Europe in order to gain experience in regulatory skills. Use of generics in European market is growing quickly due to government's price controls and # ( E ) Dr. Reddy has once again been a leader in R & D activities over the years. In fact, as stated in the case study for Dr. Reddy, the company has always looked to augment its R & D capabilities through active mergers and acquisitions. other regulations. DRL's acquisition of Betapharm provides the company with access to that market. DRL's strength in the product segment combines with Betapharm's front-end presence and thus enhancing DRL's domestic manufacturing advantage. Another factor aiding acquisition in Europe is the wider range of companies available compared to US where acquisition is more expensive and risky for Indian companies. # VIII. Conclusion To conclude, the changes in US regulations and liberalization of Indian economy have played a key role in aiding Indian firms internationalization strategies. Thus findings of the primary study support the argument that changes in world economy and its interlinked character is responsible for driving the new approaches and patterns of internationalization. Moreover, the leading Indian pharmaceutical firms show that strategy of acquisitions and direct foreign entry can result in higher profits as long as it is supplemented with superior technology. The insights from the primary study suggest that the motive behind overseas expansion of Indian firms is the need to improve global competitiveness and acquisition of assets including research. US remains the most attractive market for companies taking the export mode. Given the cost difference between India and US in terms of manufacturing, it is highly beneficial for a company to manufacture in India and export to developed nations.US remains the toughest market to enter too. Getting approval from US FDA opens the floodgates for the company to export its products to multiple countries across the world. But getting US FDA approval requires lot of time and money investment as the requirements for approval are very stringent. The second largest Pharma market in the world is Japan. Japan is supposed to be the most difficult Pharma markets to access. However, Lupin's success in establishing significant presence in Japan shows that building a footprint in this market is not impossible. Indian companies are also look at establishing their foothold in other managed but less regulated markets such as South East Asia and Africa. Liaisons in these developing markets can be facilitated more efficiently by collaborating with international agencies or via government intervention. After the thorough analysis of the pharmaceutical companies and pharmaceutical industry of India it is found that Indian Pharmaceutical companies are capitalizing on export opportunities in regulated as well as semi regulated markets. Changes in the global arena in terms of increasing healthcare cost have been able to create space and opportunities for Indian pharmaceutical players. Further change in regulatory as well as business perspective is pushing the companies to adapt and change their business strategies. As a result, companies are trying to tap newer markets for their expansion. Company size remains a big factor in determination of modes of internationalization. Size determines the financial and operational capabilities of the company. which further enables the company to take the decision of being risk averse or risk taker. 1 21: Aurobindo Pharma -basic factsHeadquartersHyderabad, IndiaPublic or PrivatePublicYear of Establishment1986Revenues (2013-14)$1.25 bnSpecialtiesR&D, Manufacturing Capabilities, Regulatory Approvalsa) Synopsis of the Company 2282: International Operations History -AurobindoPharma( E )YearModes of internationalizationCompany NameCountryFactor Motivating1998SubsidiaryUSAInternational presence1998SubsidiaryChinaInternational presence1999SubsidiaryAurobindo (H.K.) LimitedHong KongMarket access1999SubsidiaryAPL Pharma Thai LimitedThailandMarket access1999Joint VentureBrazilResource seeking1999Joint VentureChinaResource seeking2000Joint VentureUSAResource seeking, Facilitating manufacturing of formulations2001SubsidiaryAB FarmoQuimicaLimitadaBrazil2002Joint VentureUSA2003Joint VentureShanxi Tongling PharmaceuticalsChinaResource seeking for manufacturing of Penicillin.2004SubsidiaryAurex Generics LtdUK2004Joint VentureUSAThis deal helped the company to locally manufacture in USA.2005acquisitionUSFDA approved manufacturing facilityThe basic purpose was to facilitate the growth platform.inorganic growth in Europe to reduce2006AcquisitionMilpharmUKthe time to market and enhance therelationships in the generic value chain2006AcquisitionPharmacin International B.V.NetherlandsMarket seeking2007SubsidiaryJapanMarket seeking for genericsItalian operations of German2008AcquisitionTADItalypharmaceutical major TADPharmaceuticals 31: Cipla -Basic FactsHeadquartersMumbai, IndiaPublic or PrivatePublicYear of Establishment1935Revenues (2013-14)$1.6 bnSpecialtiesPharmaceuticalsa) Synopsis of the CompanyCipla have 34 manufacturing facilities thatmake Active Pharmaceutical Ingredients (APIs) andformulations, which have been approved by majorinternational Regulatory Agencies. They have 2000products in 65 therapeutic categories with over 40dosage forms. 32: International Operations History -CiplaYearModes of internationalizationCompany NameCountryMotivating Factor1984 SubsidiaryCipla USA Inc.USAfirst Indian company to receive US FDA approval2002 ExportsAnglo America, South AfricaMarket Seeking2002 Strategic AllianceMedproPharmaSouth AfricaStrategy alliance to enter the African market2011 AcquisitionManufacturing unitUgandaMarket Expansion2012 AcquisitionIntegration of value chain and strategic asset seeking2012 Joint VentureAspen PharmaAustraliaFirst Mover Advantage2013 AcquisitionCelerisCroatia2013 AcquisitionCiplaMedproSouth AfricaLow Cost Advantage, expansion and recognition2014 CollaborationTevaPharma Industries Ltd.South AfricaLow Cost Advantage2014 Licensing AgreementGileed Sciences Ltd.USATo sell and manufacture low cost medicines.2014 Joint VentureS&D PharmaU.K.Market seeking, Strategic Asset seekingto market One Dose Ready2014 Marketing AgreementBioQuiddityfusORTM in regional anestheticapplications2015 Joint ventureCooper Pharmaceuticals.MoroccoMarket seeking2015 AcquisitionOkasa Pharmaceuticals.SataraOperational and financial efficiencyCipla has been one of the largest exporters ofpharmaceutical products from India, exporting API andformulation products to over 170 countries. Thisincludes the U.S., Canada and countries in Europe,Africa, Australia, Latin America and the Middle East.Cipla started in USA in 1984, when it becamethe first Indian company to receive US FDA approval.United States of America is a key market of thecompany. Cipla USA Inc., the US subsidiary of CiplaLimited, is based in Miami, FL. The company hasexecuted over 20 US partnerships and currently hasover 40 commercialized products in the US. Cipla hassupported the development of more than 170 ANDA'sand has received 89 final approvals plus 2 NDA'sapproved and marketed in the US.CIPLA also has partnerships and alliances forproduct development, technical support and marketing.Medpro Pharmaceuticals, South Africa's first genericdrug producer formed a strategic alliance with Ciplaaround 2002. This strategic alliance gave CIPLA anoutlet to sell its products in African markets. Thestrategic alliance was later converted into a joint venture.Recently, in July 2013, Medpro Pharmaceuticals wasacquired by CIPLA for US $440 million and the companyis now known as CIPLA Medpro. 41: Dr. Reddy Labs -basic factsHeadquartersHyderabad, IndiaPublic or PrivatePublicYear of Establishment1984Revenues (2013-14)$2.25 bnSpecialtiesPharmaceuticals, Specialty, Bigeneric, API, Generic Formulationa) Synopsis of the Company 433Year 1992 Joint venture Modes of internationalization 1993 Joint venture 1994 ExportsCompany Name Biomed --Country Russia Middle East KazakhstanMotivating Factor Market Access Created two formulations units Representative office was opened.Volume XVIII Issue II Version I1994 Joint Venture 1994 Subsidiary-Dr. Reddy's Laboratories Inc.Uzbekistan USARepresentative office was opened. Target USA generic market( E )1995 Exports-BelarusRepresentative office was opened.2000 SubsidiaryReddy US Therapeutics Inc.USAdiscovery and design of novel therapeutics2000 Marketing AllianceTriomedSouth Africabegins its Generic business operation in South AfricaKunshanRotamReddy2000 Joint VenturePharmaceutical Co., Ltd.China-(KRRP)2002 acquisitionBMS Labs and its wholly owned subsidiary, Meridian UKU.K.To expand geographically and gain access to the European market.2003 Joint venturePar-Pharma Inc.USAto market hypertension products2003 Subsidiary-Russiapharmacy warehouse for better service on the territory of Russia2004 AgreementEurodrug LabsNetherlands-2004 AgreementPharmaplanSouth Africafor hiring sales force after Triomed was acquired by Aspen2004 Joint VentureVenturepharmSouth Africa2004 AcquisitionTrigenesisUSATo access strategic assets in dermatology segment.2005Sales & Development AgreementRheoscience A/S,Denmark-2006 acquisitionBetapharmaGermanyFor the purpose of brand building2006 Licensing AgreementMERCK AGGermany-2006 Licensing AgreementMolteniItaly- 51: Lupin -basic factsHeadquartersMumbai, IndiaPublic or PrivatePublicYear of Establishment1968Revenues (2013-14)$1.89 bnSpecialtiesFormulations, APIs, Generics, Biotechnology, Novel Drug Discovery and Development, Drug Delivery Systems, Specialty Pharmaceuticalsa) Synopsis of the Companyalso the fastest growing top 10 generic pharmaceuticalLupin is the 5th largest and fastest growing topplayers in Japan and South Africa (IMS).5 generics player in the US (5.3% market share byLupin benefitted from the cost arbitrageprescriptions, IMS Health) and the 3rd largest Indianbetween India and developed countries as all of Lupin'spharmaceutical company by sales. The Company ismanufacturing plants initially were located in India. From 52: International Operations History -LupinYearModes of internationalizationCompany NameCountryMotivating Factor2003 SubsidiaryLupin Pharmaceuticals Inc.USAMarket Access2004 SubsidiaryLupin Australia Pty Ltd., AustraliaAustraliaMarket Access2004 Strategic allianceBaxterUSAWill provide Lupin access to the US ceftriaxone vial market.2005 Strategic agreementGSKPhilippinesGeographical expansion2006 Acquisition51% equity in DafraPharma ltdBelgiumstrategic initiative2007 SubsidiaryLupin Atlantis Holdings SASwitzerland -Kyowa has major strengths in productdevelopment,manufacturingandmarketing of its products nationwide.2007 acquisitionKyowaJapanLupin will be able to add significantvalue through its strengths in R&D andglobal marketing, leading to majorsynergies.2008 AcquisitionGeneric HealthAustraliaBusiness expansion2008 AcquisitionPharma DynamicsSouth Africa3rd largest generic company in the SA prescriptions market.2008 Strategic AgreementASCENAUSAExtend Suprax franchise and enhance the value of brand business in the U.S."2008 AcquisitionHormosanPharmaGermany-2009 SubsidiaryLupin (Europe) Ltd.UK-2009 SubsidiaryLupinPharma Canada Ltd.Canada-2009 AcquisitionMulticare PharmaceuticalsPhilippinesacquisition offers Lupin an entry into this $2.5 billion market2010 SubsidiaryLupin Mexico S.A. de C.VMexico-IP's strong presence in the DPC hospitalsegment in Japan, through its line of2011 AcquisitionI'RompharmaceuticalsTokyoinjectable products, is an ideal fit withour existing oral business portfolio inJapan.2011 Licensing agreementSydneyAustralia-providing comprehensive therapeutic2011 Supply agreementfarmanguinkosBrazilcare in the areas of conventional TB andMDR-TB,2013 Licensing AgreementRomark LabUSAgrow its brand franchise2014 Joint ventureyoshindoJapanFirst step forward to establishing Lupin's global Biosimilar portfolio".2014 acquisitionLaboratorios grinMexicoSpecialty Ophthalmic Company; Enters the Latin American Market.2014 acquisitionNanomi B.V.Netherlandsuse of Nanomi's proprietary technology platform,2014 Joint VentureYL Biologics Ltd.Japan-2015 AcquisitionBiocomRussia-2015 AcquisitionMedquimicaBrazil- 61: Sun Pharma -basic factsHeadquartersMumbai, IndiaPublic or PrivatePublicYear of Establishment1983Revenues (2013-14)$2.56 bnSpecialtiesFormulations, API, US Generics, Specialty brands, Technically complex formulationsa) Synopsis of the CompanyOver 6.2 c) Analysis & Conclusion39Volume XVIII Issue II Version IE )(2005 Sun acquired a Hungarian firm tooperate in the controlled substance market. Companybought raw materials and dosage form manufacturingoperationsofICNHungaryfromValeantPharmaceuticals. In the same year, Sun acquired amanufacturing plant at Bryan, Ohio, USA, and workbegun on increasing the capacity and makingoperations more efficient.Sun R&D expenses & Export Intensity Sun Pharma40R & D Expensesmillion dollars) (in0 1000 2000 300020% 40% 60% 80% 100% below internationalization efforts of top 5 pharmaceutical Export Intensity Table 7.1 summarizes thecompanies by modes of internationalization.R&D ExpensesExport IntensityTotal Assets & Export Intensity Sun Pharma( E )Total Assets(in million dollars)0 50000 100000 1500000% 20% 40% 60% 80% 100%IntensityTotal AssetsExport Intensity 7Name of the firmAurobindoCiplaDr. Reddy'sLupinSun PharmaNo. of countries exporting to100170130100150No. of Acquisitions6531113No. of Joint ventures73620No. of subsidiaries31666No. of Agreements231061Sun Pharma and Lupin have been very active inmodes of internationalization by these companies. It is aacquisitions. Aurobindo has relied more on jointcomparative analysis on these companies as to whatventures whereas Dr. Reddy's has explored multiplewas a significant modes of internationalization and whatmodes of internationalization almost equally. Table 7.2was factor influencing the decision.further details out the reasons for selecting a particular 7Company NameKey Modes of taken internationalizationFactor that influenced internationalization modes ofExplanationThe Company believes that such acquisitions reduceAurobindoAcquisitionMarket Sizethe time to market and enhance the relationships in the generic value chain in addition to building abroad and formidable product portfolio.Cipla is one of the oldest pharmaceutical companiesbased in India. During it's early evolution years, itCiplaStrategic AllianceRegulatory framework of host countrycopied many patented drugs due to lax regime in India and exported them to less regulated markets. This prevented Cipla from expanding in the West as italways feared for patent infringement lawsuits due totight regulatory framework in those countries.Dr. Reddy's was the first mover in Russian market.Dr. Reddy'sJoint VentureMarket SizeIt's first ever joint venture was with Biomed of Russia and it gave Dr. Reddy unparalleled access to theRussian market. Year 2018 © 2018 Global Journals Internationalization of Indian Pharmaceutical Industry * Joint Ventures Abroad: Indian Experience, Publication Division, Ministry of Information and Broadcasting, Government of India RGAgrawal 1984 New Delhi * Intellectual Property Rights protection in Developing countries EAuriol SBiancini RPaillacar Toulouse School of Economics 2012 * The new global challengers: how 100 top companies from rapidly developing economies are changing the world? Boston Consulting Group Report 2006 Boston Consulting Group * First-mover advantages before and after TRIPS, Evidence from the Indian Pharmaceutical Industry AjayBhasakarabhatla ChirantanChatterjee 2015 Innovation and Prosperity, Stanford University Hoover institution working group on Intellectual property * The Location of Foreign Direct Investment: An Empirical Analysis NBillington Applied Economics 31 1999 * The future of multinational enterprises PJBuckley MCCasson 1976 London, Macmillan * International corporations: The international economics of foreign investment RECaves Economica 38 1971 * International comparisons: the industrial economics of foreign investment RECaves Economica 38 1971 * The internationalization of Chinese firms: A case for theoretical extensions JChild SBRodrigues Management and Organization Review 1 3 2005 * AvikChakrabarti The Determinants of Foreign Direct Investments: Sensitivity Analyses of Cross-Country Regressions 2001 54 * Post-2005 TRIPS scenario in patent protection in the pharmaceutical sector: The case of the generic pharmaceutical industry in India BiswajitDhar KMGopakumar UNCTAD, IDRC and ICTSD. Available at 2006 * Determinants of foreign direct investment flows to developing countries: a cross-sectional analysis ErdalDemirhan MahmutMasca Prague Economic Papers 4 2008. 2008 * International production and the multinational enterprises JDunning 1981 Allen & Unwin London * The eclectic (OLI) paradigm on international production: Past, present and future JDunning International Journal of the Economics of Business 8 2001 * Comment on Dragon multinationals: New players in 21 st century globalization JDunning Asia Pacific Journal of Management 23 2006 * Foreign direct investment and governments: Catalysts for economic restructuring Dunning, J. and R. Narula 1996 London, Routledge * Explaining the new wave of outward FDI from developing countries: The Case of Taiwan and Korea JDunning RHoesel 1997 22nd * Annual EIBA Conference Proceedings. Institute of International Business Stockholm * Explaining changing patterns of international production: in defense of the electric theory JHDunning Oxford Bulletin of Economics and Statistics 41 1979 * Drug Discovery Outsourcing Market in India and China SullivanFrost 2005 Research Report * Overseas Investments by Indian companies -Evolution of Policy and Trends SGopinath Keynote address at the International Conference on Indian cross-border presence/acquisitions Mumbai 2007. January 19 * The International Operations of National Firms: A Study of Direct Foreign Investment SHHymer 1976 MIT Press Cambridge, MA * Going Global: Indian Multinationals Ibef New Delhi: India Brand Equity Foundation 2007 * Tata-Corus: India's New Steel Giant TKhanna The Economic Times 2007. February 14 * Is group affiliation profitable in emerging markets? An analysis of diversified Indian business groups TKhanna KPalepu Journal of Finance 55 2 2000 * KKumar Mcleod Multinationals from developing countries MG 1981 * MALexington LexingtonBooks * NKumar 1996 * India: industrialization, liberalization and inward and outward foreign direct investment Foreign Direct Investment and Governments HJohn RajneeshDunning Narula London, Routledge * Emerging outward foreign direct investment from Asian developing countries: prospects and implications NKumar Harvard Business Review N. Kumar et al. 1998. March-April Strategies for local companies in emerging markets * Globalization, Foreign Direct Investment and Technology Transfers NKumar 2003 London and New York: Routledge * Emerging TNCs: trends, patterns and determinants of outward FDI by Indian enterprises NKumar Transnational Corporations 16 1 2007 * RBLall Multinationals from the Third World: Indian Firms Investing Abroad Delhi Oxford University Press 1986 * The new multinationals: The spread of third world enterprises SLall 1983 Chichester, Wiley * The New Multinationals: The Spread of Third World Enterprises SLall 1983 John Wiley & Sons New York Multinationals from India in S. Lall * The New Multinationals SLall 1984 New York, Wiley * Outward direct investment by Indonesian firms: Motivation and effects DJLecraw Journal of International Business Studies 24 1977 * direct investment by firms from less developed countries DJLecraw Oxford Economic Papers 29 1977 * Competitive advantages of the late comer firm: A resource based account of industrial catch-up strategies JAMathews Asia Pacific Journal of Management 19 2002 * Dragon Multinationals: New players in 21st century globalization JAMathews Asia Pacific Journal of Management 23 2006 * Indian Investments Abroad: What Explains the Boom? RNagaraj Economic and Political Weekly XLI 46 2006 * The Internationalization of Firms from India: Investment, Mergers and Acquisitions DNayyar SLPTMD, Working Paper Series #004 2007 University of Oxford * The determinants of outward foreign direct investment: A firm level analysis of Indian manufacturing JPPradhan Oxford Development Studies 32 4 2004 * Growth of Indian Multinationals in the World Economy: Implications for Development JPPradhan 2007a. 2007/04 New Delhi Institute for Studies in Industrial Development ISID Working Paper * Trends and Patterns of Overseas Acquisitions by Indian Multinationals JPPradhan 2007. 2007 New Delhi Institute for Studies in Industrial Development ISID Working Paper * The Evolution of Indian Outward Foreign Direct Investment: Changing Tends and Patterns JPPradhan International Journal of Technology and Globalization 4 2008 * Overseas Mergers and Acquisitions by Indian Enterprises: Patterns and Motivations JPPradhan VAbraham Indian Journal of Economics LXXXV 2005 * Who is interested in Biotech? R & D strategies, knowledge base and market sales of Indian biopharmaceutical firms SRamani Research Policy 31 3 2002 * Strengthening the patent regime: Benefits for developing countries -A Survey RSharma KKSaxena Journal of Intellectual property rights 17 2012 * EEC tariffs and U.S. direct investment AndrewSchmitz JurgBieri European Economic Review 3 1972. 1972 * Emerging Asian MNEs and their internationalization strategies: case study evidence on Taiwanese and Singaporean firms ABSim JRPandian Asia Pacific Journal of Management 20 1 2003 * World investment report 2004: The shift towards services Unctad Geneva, United Nations Conference on Trade and Development 2004 * Unctad FDI from Developing and Transition Economies: Implications for Development New York and Geneva 2006. 2006 * International investment and international trade in the product life cycle RVernon Quarterly Journal of Economics 80 1966 * Third World Multinationals: The Rise of Foreign Investment from Developing Countries LTWells Jr 1983 MIT Press Cambridge, MA * The internationalization of ethnic Chinese business firms from South East Asia: Strategies, processes and competitive advantages HYeung International Journal of Urban and Regional Research 23 1 1999